Biotin, also known as vitamin B7, has not been shown to cause or prevent cancer in humans based on current evidence. But the relationship between this common supplement and cancer is more tangled than that simple reassurance suggests. Cancer cells gobble up biotin at elevated rates, biotin-dependent enzymes fuel tumor metabolism, high-dose biotin supplements can falsify cancer-related blood tests, and researchers are now deliberately attaching chemotherapy drugs to biotin molecules to sneak them into tumors. For anyone taking biotin supplements or undergoing cancer screening, these intersections matter in practical ways.
Why Cancer Cells Want More Biotin
Most people know biotin as a hair-and-nails vitamin. Inside cells, though, biotin serves as an essential helper molecule for a handful of enzymes involved in building fatty acids, processing amino acids, and generating energy from sugars. These enzymes, called biotin-dependent carboxylases, include acetyl-CoA carboxylase and pyruvate carboxylase, among others. They are central to the metabolic machinery every cell uses to grow and divide.
Cancer cells, which grow and divide far faster than normal cells, have an outsized appetite for the products of these enzymes. Fatty acid synthesis, in particular, ramps up dramatically in many tumors because rapidly dividing cells need to build new membranes. Acetyl-CoA carboxylase, one of the key biotin-dependent enzymes, catalyzes the rate-limiting step in fatty acid production. Researchers have found that this enzyme is sometimes overexpressed in cancer cells, and that blocking it can trigger cancer cell death and halt their growth cycle.1PubMed. The acetyl-CoA carboxylase enzyme: a target for cancer therapy? That connection has made acetyl-CoA carboxylase a target for potential anti-tumor drugs.2PubMed Central. Targeting acetyl-CoA carboxylase 1 for cancer therapy
Pyruvate carboxylase, another biotin-dependent enzyme, plays a different but equally important role. It replenishes the energy cycle that cells use to fuel biosynthesis. Studies on breast cancer have found that pyruvate carboxylase is expressed at higher levels in cancerous breast tissue than in surrounding healthy tissue, and that its levels correlate with tumor size and stage.3PLOS ONE. Pyruvate Carboxylase Is Up-Regulated in Breast Cancer and Essential to Support Growth and Invasion of MDA-MB-231 Cells When researchers silenced pyruvate carboxylase in aggressive breast cancer cell lines, those cells showed roughly a 50% drop in proliferation, migration, and invasive ability. Breast cancer cells that have spread to the lungs appear to depend on this enzyme even more heavily, activating it in response to the lung environment.4PubMed Central. Pyruvate carboxylase supports the pulmonary tropism of metastatic breast cancer
None of this means biotin itself is driving cancer. Rather, cancer cells co-opt biotin-dependent metabolic pathways that already exist in healthy cells, running them harder to support rapid growth. The enzymes need biotin to function, so tumors have an incentive to import more of it.
Overexpressed Biotin Transporters on Tumor Cells
To pull in extra biotin, many cancer cells ramp up production of the sodium-dependent multivitamin transporter, or SMVT, which is the primary gateway for biotin uptake into cells. Lab work comparing breast cancer cells (T47D) with normal breast cells (MCF-12A) found that the cancer cells expressed SMVT at higher levels and could import more of the vitamin, likely to sustain their elevated metabolic demands.5PubMed. Biotin uptake by T47D breast cancer cells: functional and molecular evidence of sodium-dependent multivitamin transporter (SMVT) This pattern is not limited to breast cancer. SMVT overexpression has been observed across a range of aggressive cancer types, including ovarian, lung, colon, renal, and leukemia cell lines.6PubMed Central. Imaging Biotin Trafficking In Vivo with Positron Emission Tomography
This overexpression creates a vulnerability that researchers have been eager to exploit, which is where biotin starts to become a tool against cancer rather than merely a bystander in tumor biology.
Using Biotin to Deliver Cancer Drugs
If cancer cells are hungrier for biotin than healthy cells, a logical strategy is to attach anti-cancer drugs to biotin molecules and let the tumor’s own import machinery pull the drugs inside. This idea has generated a substantial body of research over the past decade, and the results so far are promising in laboratory settings.
The basic approach involves conjugating biotin to a chemotherapy agent. When the resulting molecule reaches a tumor cell with overexpressed biotin receptors, the cell eagerly absorbs it, getting a dose of the drug along with the expected vitamin. Researchers have tested this with several drug platforms. Biotin-tagged versions of paclitaxel, a widely used chemotherapy drug, were delivered to non-small-cell lung cancer cells using a specially engineered carrier system. The biotin-tagged version penetrated both cell layers and three-dimensional tumor models more effectively than the drug alone or the carrier without biotin, and showed greater tumor-killing activity.7PubMed. Biotin functionalized PEGylated poly(amidoamine) dendrimer conjugate for active targeting of paclitaxel in cancer
A similar approach used biotin to direct doxorubicin, another common chemotherapy drug, toward HeLa cells (a cervical cancer line). The biotin-tagged nanoparticles showed specific binding to cells with overexpressed biotin transporters and released the drug in response to the high levels of reactive oxygen species found in tumor environments.8PubMed Central. Biotinylated Bilirubin Nanoparticles as a Tumor Microenvironment‐Responsive Drug Delivery System for Targeted Cancer Therapy Another team designed biotin-coupled nanoparticles loaded with gemcitabine, a chemotherapy drug used against pancreatic and other cancers, and confirmed that the biotin targeting enhanced selective uptake by cancer cells in lab tests.9PubMed Central. Biotin-Decorated PAMAM G4.5 Dendrimer Nanoparticles to Enhance the Delivery, Anti-Proliferative, and Apoptotic Effects of Chemotherapeutic Drug in Cancer Cells
A 2024 review cataloguing these efforts describes two main categories: small-molecule-biotin conjugates and nano-biotin conjugates, both designed to increase drug uptake at the tumor while minimizing damage to normal tissue.10PubMed. Recent advances in biotin-based therapeutic agents for cancer therapy It is worth emphasizing that these are still experimental technologies. None has yet been approved for routine clinical use in humans, but the concept is active across many research groups worldwide.
Biotin in Cancer Imaging and Radioimmunotherapy
Beyond drug delivery, biotin’s affinity for tumor cells is being harnessed for imaging and radiation-based treatments. Researchers have developed a radioactive form of biotin (labeled with carbon-11) for use in PET scans, which could help visualize tumors that overexpress the SMVT transporter. This approach might eventually be useful both for cancer diagnosis and for understanding how biotin transport changes during tumor development.6PubMed Central. Imaging Biotin Trafficking In Vivo with Positron Emission Tomography
A separate imaging strategy uses biotin in a “pretargeting” system. Instead of attaching the radioactive tracer directly to a large antibody molecule (which takes days to clear from the blood, causing background radiation), researchers first inject an antibody linked to streptavidin, a protein that binds biotin with extraordinary strength. After the antibody homes in on the tumor and excess is cleared from the bloodstream, a small radioactive biotin molecule is injected. It quickly finds and latches onto the streptavidin already sitting on the tumor surface, lighting it up on a PET scan with less background noise.11PubMed. PD-L1 ImmunoPET on the basis of Avidin/Biotin pre-targeted cancer imaging
The same streptavidin-biotin chemistry works for therapy, not just imaging. In pretargeted radioimmunotherapy, the radioactive biotin carries a therapeutic dose of radiation instead of just a tracer dose. This strategy has been tested in lymphoma models and can deliver higher doses of radioactivity to tumors than conventional radioimmunotherapy approaches.12PubMed Central. Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma The two-step process, with a clearing agent given between the antibody injection and the radiolabeled biotin injection, helps spare healthy tissue.13PubMed. Role of biotin-binding affinity in streptavidin-based pretargeted radioimmunotherapy of lymphoma
How Biotin Supplements Can Falsify Cancer-Related Lab Tests
Here is where the biotin-cancer connection becomes immediately practical for supplement users. Many common blood tests use a laboratory technique that relies on the strong binding between biotin and streptavidin to measure levels of hormones, vitamins, and disease markers. If you have excess biotin floating in your blood from a supplement, it competes with the biotin built into the test, throwing off the results.
The FDA issued a safety communication about this problem after receiving reports of adverse events caused by misleading lab results. The interference affects a wide range of tests, including those for thyroid markers, hormones, cardiac biomarkers, and cancer markers.14PubMed. Biotin interference in immunoassays based on biotin-strept(avidin) chemistry: An emerging threat This is not a theoretical concern. At daily doses in the range of 100 to 300 mg, the kind sometimes taken for multiple sclerosis or other conditions, biotin can produce clinically significant errors. A case report documented an oncology patient on immunotherapy whose thyroid-stimulating hormone readings were thrown off by biotin supplementation, complicating the monitoring of a treatment known to cause thyroid side effects.15PubMed. Biotin-induced thyroid stimulating hormone aberrations in the setting of immunotherapy
The FDA recommended that healthcare providers, laboratory personnel, and consumers be aware of the issue, though it did not specify exactly how long to stop biotin before blood draws due to variability across different test platforms.16The Journal of Applied Laboratory Medicine. AACC Guidance Document on Biotin Interference in Laboratory Tests – Section: Recommendations from the FDA and In Vitro Diagnostic Test Manufacturers The practical takeaway: if you take biotin supplements, especially at high doses, tell your doctor and lab before any blood work. This is particularly important if the tests involve cancer markers, thyroid panels, or cardiac biomarkers, since a falsely reassuring or falsely alarming result could lead to wrong decisions about treatment.
Biotinidase as a Cancer Biomarker
Biotinidase is the enzyme that recycles biotin in the body, freeing it from proteins so it can be reused. Intriguingly, reduced biotinidase activity and expression keep turning up in connection with certain cancers. In a study comparing blood samples from breast cancer patients with healthy controls, biotinidase levels were significantly lower in the cancer group across nearly all tumor grades.17PubMed Central. Differential profiling of breast cancer plasma proteome by isotope-coded affinity tagging method reveals biotinidase as a breast cancer biomarker This finding has spurred interest in using serum biotinidase as a diagnostic and prognostic marker for breast cancer.18Jentashapir Journal of Cellular and Molecular Biology. Biotinidase, as a Convenient Diagnostic and Prognostic Marker for Breast Cancer
The pattern extends beyond breast tissue. In papillary thyroid cancer, biotinidase expression was decreased compared to benign thyroid nodules. More aggressive thyroid tumors showed an even greater drop, and loss of biotinidase expression was associated with poorer disease-free survival, with roughly three times the hazard of recurrence.19PLOS ONE. Biotinidase is a Novel Marker for Papillary Thyroid Cancer Aggressiveness Why tumors would suppress biotinidase is not yet fully understood, but it raises the possibility that disrupted biotin recycling plays some functional role in cancer progression rather than being a mere bystander.
Biotin’s Epigenetic Fingerprints
One of the more fascinating threads in this field involves biotin’s role in controlling which genes are turned on or off. Inside every cell, DNA is wound around proteins called histones. Chemical modifications to these histones act like switches, making certain stretches of DNA more or less accessible for reading. Biotin gets attached to histones through a process called biotinylation, and evidence suggests that this plays roles in gene silencing, in keeping chromosomes properly condensed during cell division, and in the cell’s response to DNA damage.20PubMed Central. Epigenetic regulation of chromatin structure and gene function by biotin
These are exactly the kinds of processes that go haywire in cancer. If biotin helps keep certain genes silenced and supports DNA repair, then disruptions to biotin-dependent epigenetic regulation could theoretically contribute to genomic instability. Research has also linked the enzyme holocarboxylase synthetase, which attaches biotin to both carboxylases and histones, to the regulation of tumor-suppressing gene products.21PubMed Central. Novel roles of holocarboxylase synthetase in gene regulation and intermediary metabolism A review on gut microbiota and colon cancer noted that biotin produced by intestinal bacteria might exert epigenetic effects similar to those of folate, influencing cell proliferation through its effects on DNA transcription, replication, and repair.22The Journal of Nutrition. Products of the Colonic Microbiota Mediate the Effects of Diet on Colon Cancer Risk
The evidence here is still early-stage. Nobody has demonstrated in humans that biotin supplementation alters cancer-relevant epigenetic marks in a clinically meaningful way. But the mechanistic pieces are suggestive enough that researchers continue to investigate.
Does Dietary Biotin Intake Affect Cancer Risk?
Given everything above, you might wonder whether the amount of biotin you eat or supplement with influences your chances of developing cancer. The honest answer is that almost no large-scale epidemiological data directly addresses this question. One dietary survey conducted in South Australia found that people in the highest third of biotin intake had a 65% higher frequency of micronuclei, which are small DNA-containing bodies that form when chromosomes break or fail to separate properly during cell division, compared to those in the lowest third of intake.23Oxford Academic. Low intake of calcium, folate, nicotinic acid, vitamin E, retinol, β-carotene and high intake of pantothenic acid, biotin and riboflavin are significantly associated with increased genome instability—results from a dietary intake and micronucleus index survey in South Australia Higher micronucleus counts are a marker of genomic instability, which is associated with cancer risk over time.
That single study is notable but far from definitive. It was observational, meaning it could not prove that biotin caused the genomic instability. People who eat more biotin also eat more of many other nutrients, and disentangling those variables is extremely difficult. No randomized trial has tested whether biotin supplementation affects cancer incidence or micronucleus frequency. For now, this finding sits in the category of “warrants further investigation” rather than “change your behavior.”
At normal dietary intakes and typical supplement doses used for hair and nails (usually 2.5 to 10 mg per day), there is no established evidence that biotin increases cancer risk. The adequate intake for adults is only 30 micrograms per day, so even modest supplements represent a large multiple of what the body typically needs, but the cancer-specific data simply does not exist to say whether that matters.
Biotin Deficiency and Immune Function
The flip side of asking whether too much biotin is harmful is asking whether too little biotin affects the body’s ability to fight cancer. Biotin deficiency is uncommon in healthy people eating a varied diet, but it can occur in certain situations, including during prolonged antibiotic use, in people with genetic biotinidase deficiency, or during pregnancy.
Lab research on human immune cells found that biotin-deficient conditions pushed dendritic cells, which are key orchestrators of immune responses, toward a more inflammatory profile. Specifically, dendritic cells cultured without adequate biotin and then activated produced higher levels of signals that promote a particular type of inflammatory immune response.24PubMed Central. Biotin deficiency enhances the inflammatory response of human dendritic cells Whether this matters for cancer surveillance in real patients is unknown. The immune system’s ability to recognize and destroy cancer cells depends on a complex interplay of factors, and no clinical study has linked biotin deficiency to worse cancer outcomes. But the finding adds another layer to the broader picture: biotin status may subtly influence the immune environment, for better or worse.
Practical Considerations for Supplement Users
If you take biotin for cosmetic reasons or because a doctor recommended it, the cancer connection is not a reason to panic. There is no clinical evidence that standard biotin supplements promote tumor growth in humans. The fact that cancer cells overexpress biotin transporters does not mean that taking biotin feeds existing tumors any more than eating sugar “feeds” cancer, a common misconception that oversimplifies how nutrients are used.
The most actionable concern is lab test interference. A few guidelines to keep in mind:
- Disclose supplements: Tell your doctor and the lab about any biotin-containing supplements before blood work, especially tests for thyroid function, cardiac markers, or tumor markers.
- Check multivitamins: Many multivitamins and “beauty” supplements contain biotin, sometimes at doses far above the adequate intake. Read the label.
- Timing matters: While the FDA did not specify an exact washout period, many laboratories suggest stopping high-dose biotin at least 48 to 72 hours before testing. Ask your provider for specific guidance based on your dose.
- Dose context: Interference risk scales with dose. Someone taking 30 micrograms in a basic multivitamin faces a very different risk than someone taking 10 mg for hair growth or 100 to 300 mg for a neurological condition.25PubMed Central. Clinically Significant Lab Errors due to Vitamin B7 (Biotin) Supplementation: A Case Report Following a Recent FDA Warning
For cancer patients specifically, the interference issue is compounded by the stakes involved. A falsely low tumor marker could provide false reassurance, while a falsely abnormal thyroid test during immunotherapy could trigger unnecessary treatment changes. The case literature on this is still small, but the potential consequences are serious enough to justify vigilance.
Biotin-Tagged Drugs and the Future of Targeted Therapy
The most exciting aspect of the biotin-cancer intersection for patients may ultimately be on the treatment side. The idea of using a vitamin the tumor already craves as a Trojan horse for chemotherapy drugs is elegant, and the lab-bench results have been consistently encouraging across multiple drug types and cancer cell lines. Researchers have also begun exploring biotin as a targeting ligand alongside other site-localizing molecules like folate and specific peptide sequences, building multifunctional drug systems with built-in selectivity for cancerous tissue.26PubMed. Disulfide-based multifunctional conjugates for targeted theranostic drug delivery
The gap between lab success and bedside availability remains wide. Targeted nanoparticle systems face hurdles in manufacturing consistency, long-term stability, and proving that their improved selectivity in cell cultures translates to better outcomes in living patients. But the principle is sound, and biotin-based targeting continues to attract serious investment. For people watching this space, the vitamin in your supplement bottle may one day find its most important medical role not as a nutrient but as a cancer drug’s address label.